Scientific Abstracts
Background: Fracture Liaison Services (FLS) can prevent secondary fracture through systematic identification of low trauma fractures using dedicated case finding, with assessment and treatment of osteoporosis where necessary. Services are now being measured for quality against Clinical Standards for Fracture Liaison Services published by the National Osteoporosis Society in 2015.
[1] The first standard asserts that all patients over 50 years with a newly reported vertebral fracture will be systematically and proactively identified. Objectives: To evaluate provision for systematic identification of newly reported vertebral fractures in patients aged over 50 at Fracture Liaison Services (FLS) across the UK. Methods: A gap analysis tool was used to measure service provision against standard one of the Clinical Standards for Fracture Liaison Services, relating to the systematic and proactive identification of vertebral fractures. Data was collected at 78 sites in the UK. Results: 63% (49) of sites had no systematic process in place to identify vertebral fractures. Only 10% (8) sites identified all newly reported vertebral fractures. 27% (21) had procedures in place to identify some vertebral fractures, i.e. those within certain cohorts. There was considerable disparity across the UK. Sites in Scotland were significantly more likely to have comprehensive processes in place (38%, 6/16) than in the rest of the UK (3%, 2/62). Conclusions: Systematic identification of vertebral fractures poses a particular challenge to services due to a number of factors. Vertebral fractures are difficult to identify as they tend not to present or be admitted in acute settings where FLS are primarily based. In addition, services require support from Radiology, including a commitment to avoid ambiguous terminology when reporting vertebral fractures. Furthermore, as a category, vertebral fractures fall between departments (Rheumatology, Orthopaedic, Fracture Clinic, A&E, Spinal services) making systematic identification even more challenging. In the Fracture Liaison Service Database Facilities Audit (May 2016), the most frequently cited barrier to the identification of vertebral fractures was lack of a patient pathway.
[2] Gap analysis shows a paucity of provision in the identification of vertebral fractures. This is the key driver for work underway in the NOS to develop a patient pathway for vertebral fractures, in conjunction with clinical experts, to promote best practice and best patient care. Background: Minimum biodrug concentrations of ∼7mg/l are predictive of disease remission 1 . Very low/absent biodrug concentrations associate with loss of benefit which may be due to ADA 2 however the clinical utility of ADA is assay dependant. In rheumatoid arthritis the combination of low/absent drug concentration and the presence of ADA appears to have the greatest utility 3 . Canterbury Health Laboratories, New Zealand (CHL) has developed a competitive binding ELISA to detect neutralising antibodies whereas most commercial assays utilise a bridging methodology Objectives: Compare performance of a competitive binding assay with two commercial bridging assays in the detection of ADA to anti-TNFα biodrugs in serum samples with low/absent biodrug concentration Methods: Serum samples referred for anti TNF biodrug concentrations found to have very low/undetectable concentrations (<1mg/l) were tested for ADA using the competitive-bind assay and two bridging assays (TANI Medikal and GRIFOLS) Results: Over a 22 month period (Jan 2014 -Oct 2016), 67% (331/497) of referred samples had biodrug concentrations below 7mg/l and 15% (n=79) had low/undetectable biodrug concentrations (adalimumab n=36 or infliximab n=43). ADAs were detected in 53% ( 
